Industry collaboration and randomized clinical trial design and outcomes

JAMA Internal Medicine

Volumn 174, Issue 10, 2014, Pages 1695-1696

  Roper, Nitin ^a   Zhang, Nasen ^b   Korenstein, Deborah ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c AMERICAN COLLEGE OF PHYSICIANS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOR PROFIT ORGANIZATION; FUNDING; HUMAN; INDUSTRY; INTENTION TO TREAT ANALYSIS; LETTER; METHODOLOGY; ORGANIZATION; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; TREATMENT OUTCOME; COOPERATION; DRUG INDUSTRY; ECONOMICS; FINANCIAL MANAGEMENT; INTERPERSONAL COMMUNICATION; JOURNAL IMPACT FACTOR; PROCEDURES;

COOPERATIVE BEHAVIOR; DISCLOSURE; DRUG INDUSTRY; HUMANS; JOURNAL IMPACT FACTOR; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; TREATMENT OUTCOME;

EID: 84907990886     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.3590     Document Type: Letter

References (3)

1. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012; 12:MR000033.
2. Tuech JJ, Moutel G, Pessaux P, Thoma V, Schraub S, Herve C. Disclosure of competing financial interests and role of sponsors in phase III cancer trials. Eur J Cancer. 2005; 41(15):2237-2240.
3. Krauth D, Anglemyer A, Philipps R, Bero L. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: ameta-analysis. PLoS Biol. 2014; 12(1):e1001770.